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Despite the potential importance of senescence in tumour suppression, its effector mechanism is poorly understood. Recent studies
suggest that alterations in the chromatin environment might add an additional layer of stability to the phenotype. In this review, recent
discoveries on the interplay between senescence and chromatin biology are overviewed.
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Cellular senescence was first described as a state of permanent cell
cycle arrest resulting from the replicative exhaustion of cultured
normal diploid cells (Hayflick, 1965). Despite the static appearance
and steady state of senescent cells, they are viable and
metabolically active. Senescent cells exhibit a large and flat
morphology with vacuoles, and an enlarged nucleus. Besides the
morphological changes, the best-known marker is senescence-
associated b-galactosidase activity (Dimri et al, 1995). More
recently it has been shown that senescence is often accompanied
by specific alterations of the chromatin structure, known as
senescence-associated heterochromatic foci (Narita et al, 2003).
The senescence phenotype is extremely stable and, in contrast to
quiescent cells (readily reversible cell cycle arrest), senescent cells
are unresponsive to mitogenic stimuli such as serum or growth
factors. Thus, senescence seems to be antithetical to ‘immortalisa-
tion’ in cultured cells and limits their neoplastic transformation.
However, confirmation in vivo of this in vitro concept did not
emerge until recently. A recent series of studies identified
senescent cells in vivo using various models, thus reaffirming the
significance of senescence as an intrinsic tumour suppressor
pathway (Braig et al, 2005; Chen et al, 2005; Collado et al, 2005;
Lazzerini Denchi et al, 2005; Michaloglou et al, 2005). Never-
theless, the molecular mechanism of senescence, particularly how
senescent cells are driven into such a stable arrest, is not yet clear.
To address this question, we have focused on the chromatin
changes that occur during senescence and we have proposed that
epigenetic regulation of gene expression might be involved in this
process at least in vitro (Narita et al, 2003, 2006). Here the clinical
significance of senescence as well as the role of chromatin
alteration as an effector mechanism of senescence are discussed
(Table 1).
SENESCENCE AND AGEING
Originally, cellular senescence and organismal ageing were
believed to be different concepts, yet it has been suggested that
they are closely related owing to their shared ability to limit
‘lifespan’. Indeed, fibroblasts isolated from older individuals or
patients with premature ageing syndrome such as Werner
syndrome exhibit SA-b-gal activity earlier than those from young
or healthy individuals, respectively. In addition, some senescence-
associated genes, such as p53, can influence organismal lifespan.
However, a direct causative effect of cellular senescence on ageing
has never been shown. Now new studies shed light on this
question; senescence may play a role in suppressing age-related
cancer risk at the expense of juvenescence (Janzen et al, 2006;
Krishnamurthy et al, 2006; Molofsky et al, 2006).
Ageing is associated with a reduction in the regenerative
capacity of tissues, for which the functional progenitor cells are
critical. An attractive idea is that senescence of the progenitor cells
can be a cause of functional and physiological decline in tissue
homeostasis and, as a consequence, individual ageing. A recent
series of studies provided strong and direct insights into this
senescence-ageing association (Janzen et al, 2006; Krishnamurthy
et al, 2006; Molofsky et al, 2006). These reports showed that the
age-dependent increase of p16 expression, an important marker as
well as a mediator of cellular senescence, is associated with the
limitation of self-renewal activity in the regenerative cells and
contributes to ageing in bone marrow, brain and pancreatic islets
(Janzen et al, 2006; Krishnamurthy et al, 2006; Molofsky et al,
2006). These studies raised the possibility that senescence of stem/
progenitor cell compartments can, at least partially, be a direct
cause of organismal ageing. The expression of the p16 tumour
suppressor gene might balance the age-related risk for tumour
development in stem/progenitor cell compartments (Figure 1).
REPLICATIVE EXHAUSTION AND DNA
DAMAGE-INDUCED SENESCENCE
The ‘replicative exhaustion’ that triggers senescence is essentially
the erosion of telomeres. The telomeric regions found at the ends
of chromosomes contribute to genomic stabilisation, and are
shortened after each replication cycle. Once telomeres become
critically short, they trigger senescence. Consistently, expression of
telomerase, a reverse transcriptase that elongates telomeres, allows
cells to proliferate beyond their normal replicative capacity and,
accordingly, most cancer cells aberrantly express telomerase.
The senescence phenotype can be induced in early passage cells
by a variety of cellular stresses, including DNA damage, oncogenic
stress, oxidative stress and suboptimal culture conditions.
Telomere-associated replicative senescence is often considered to
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www.bjcancer.combe the ‘prototype’ of senescence and discriminated from other
types of stress-induced senescence, which are telomere indepen-
dent. However, the cause of telomere-associated senescence is
attributed to the DNA damage response triggered by telomere
dysfunction, and an intact DNA damage response is crucial for the
induction of senescence (d’Adda di Fagagna et al, 2003; Herbig
et al, 2004). Therefore, replicative senescence also boils down to
stress-induced senescence.
Regardless of the trigger, senescent cells accumulate activity of
the p53 and p16/Rb tumour suppressor pathways, both of which
are commonly disabled in many cancers. It has been proposed that
senescence can confer a physiological barrier to uncontrolled cell
proliferation of damaged or aberrant cells, and therefore serves as
intrinsic or therapeutic tumour suppressor machinery.
The clinical relevance of DNA damage-induced senescence was
demonstrated by the studies that indicated that SA-b-gal-positive
cells are present in tumours after chemotherapy, which causes
DNA damage, in human breast cancer and in a mouse lymphoma
model (Schmitt et al, 2002; te Poele et al, 2002). In the mouse
model, DNA damage induces senescence in lymphoma tissues
when the cells ‘cannot die’ owing to enforced expression of bcl-2,
an antiapoptotic factor (Schmitt et al, 2002). Given the fact that
immortalised cells, which ‘cannot senesce’, are very sensitive to
DNA damage-induced apoptosis and that generally senescent cells
are resistant to apoptosis, cells appear to have the ability to
cleverly handle cellular insults based on a fine-tuned balance
between apoptosis and senescence.
OIS
Among the stress-induced senescence phenotypes, oncogene-
induced senescence (OIS) draws wider attention particularly after
the recently emerging evidence of its clinical implications.
Enforced expression of a constitutively active form of mutant ras
promotes transformation in immortalised cells. However, the fact
that oncogenic ras fails to transform normal cells and, para-
doxically, can cause cell cycle arrest was known as an inexplicable
phenomenon (Hirakawa and Ruley, 1988). Almost 10 years after
this initial observation was made, more careful characterisation of
oncogenic ras-induced cell cycle arrest lead to the identification of
OIS, which is phenotypically indistinguishable from replicative
senescence in normal diploid cells (Serrano et al, 1997). This
process requires the intact mitogen-activated protein kinase
(MAPK) pathway, the kinase downstream of ras. In marked
contrast to other prosenescent stimuli, constitutively active
mitogenic stimuli triggered by oncogenic ras initially cause rapid
cell proliferation, which even accompanies loss of contact growth
inhibition, a hallmark of cancer. This initial burst of proliferation
is followed by the activation of at least two tumour suppressor
pathways, the p53 and p16/Rb pathways, which counteract the
mitogenic activity of ras and eventually override cell proliferation
(Figure 2). In fact, the bypass of senescence in human cells
requires inactivation of both the p53 and p16/Rb pathways
(Serrano et al, 1997). The delayed kinetics of the accumulation
of tumour suppressor gene products triggered by the abnormal
mitogenic stimuli suggests that OIS is an intrinsic antitumour
response that monitors cells to be sure that their proliferation is
within an allowable range, although how cells determine the
proliferation threshold and sense the deviation from it that triggers
the execution of the senescent arrest is still unknown. Even if the
theory makes perfect sense, the significance of senescence as a
tumour suppressor mechanism in vivo remains controversial.
In 2005, a series of reports altogether provided strong evidence
to support the clinical relevance of OIS as bona fide tumour
suppressor machinery in various model systems in human and
mouse. These studies identified senescent cells in premalignant or
benign, but not in malignant, tissues such as BRAF (downstream
Table 1 Localisation and function of chromatin factors
Localisation and function
Chromatin factors General Senescence
HPI Heterochromatin SAHF component
H3 K9me3 Heterochromatin SAHF component
MacroH2A Heterochromatin SAHF component
HMGA1/2 Chromatin architecture SAHF component
Histone H1 Linker histone Depleted
H3 K9 acetyl Euchromatin Excluded from SAHF
H3 K4methyl Euchromatin Excluded from SAHF
HIRA Histone chaperone SAHF regulation
Asf1a Histone chaperone SAHF regulation
HMGA¼high-mobility group A; HP1¼heterochromatin protein 1; SAHF¼senes-
cence-associated heterochromatic foci.
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Figure 1 Balance between ageing and cancer. Age-dependent upregula-
tion of p16 in stem/progenitor compartments might contribute to tumour
suppression and ageing.
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Figure 2 Oncogene-induced senescence (OIS). Constitutively active
mitogenic stimuli induces rapid cell proliferation, but somehow the
senescence machinery is triggered and eventually overcomes the mitogenic
activity.
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tumours of melanocytes) (Michaloglou et al, 2005), Kras-
associated lung adenomas or pancreatic intraductal neoplasias
(Collado et al, 2005), AKT-PTEN-related prostatic intraepithelial
neoplasia (Chen et al, 2005), and mitogenic E2F3-associated
hyperplasia in pituitary glands (Lazzerini Denchi et al, 2005).
Importantly, these oncogenic lesions result in full-blown cancers
if they are combined with other mutations that disable the
senescence machinery (such p53, Rb and INK4a-ARF locus
mutations) in some model systems. These data suggest that an
initial oncogenic lesion promotes hyperproliferation in the tissues,
but subsequent provocation of OIS contributes to restrict tumour
progression from a benign to a malignant state. Questions
remaining to be answered include how generally benign tumours
involve senescence machinery: do all benign tumours contain
senescent cells and does OIS happen so often in our bodies as one
can imagine from the example of moles (Michaloglou et al, 2005)?
Ultimately, why are benign tumours benign?
In summary, cellular senescence, once suspected to be a cell
culture artefact, is now more convincingly linked to pathophysio-
logy of organismal ageing, DNA damage response and oncogenic
stress.
EPIGENETIC REGULATION DURING SENESCENCE
Generally, the senescence phenotype progressively accumulates
over multiple cell cycles and senescent cells, much like differ-
entiated cells, exhibit a specific gene expression profile. These
observations suggest an active involvement of epigenetic gene
regulation. Consistent with this view, certain types of cells exhibit
senescent arrest that is accompanied by senescence-associated
heterochromatic focis (SAHFs), a new type of facultative hetero-
chromatin (Narita et al, 2003). Such drastic chromatin rearrange-
ment can also be observed during some types of cellular
differentiation, another state of stable cell cycle arrest (Francastel
et al, 2000). Very little is known about the effector mechanism of
cellular senescence, but the global chromatin reorganisation may
not simply be a senescence marker, but rather play a key role in the
senescence mechanism. In fact, there is a strong correlation
between SAHF formation and the irreversibility of the senescence
phenotype (Beausejour et al, 2003; Narita et al, 2003).
The kinetics of the accumulation of SAHF-positive cells after
triggering senescence by ras is well correlated with that of other
indicators of senescence, such as SA-b-gal activity, p16 induction,
Rb hypo-phosphorylation and cell cycle arrest; and SAHFs and
DNA synthesis are mutually exclusive events (Narita et al, 2003).
Senescence-associated heterochromatic focis are enriched for
markers of heterochromatin, such as heterochromatin protein 1
(HP1) and Lys9 tri-methyl (K9me3) of histone H3 (which confers a
docking site to HP1), and exclude euchromatic markers, such as
histone H3 K9 acetyl and K4me3 (Narita et al, 2003) (Figure 3).
Interestingly, SAHF formation is largely dependent on the
p16/Rb pathway in ras-induced senescence, although the impact of
p53 on SAHF is marginal (Narita et al, 2003). p16 is an inhibitor of
D-type cyclin-dependent kinases (CDKs). CDKs phosphorylate the
Rb family of proteins, which are negative regulators of E2F
transcription factors and, as a consequence, release the repression
of E2F-target cell cycle genes. Knockdown of p16 or Rb
significantly suppresses SAHF formation after ras introduction
into human diploid fibroblasts, yet those p16 or Rb-deficient cells
are still arrested and exhibit the prototypic senescence morphology
and SA-b-gal activity. Interestingly, these SAHF-negative ‘senes-
cent cells’ show deregulation of some cell cycle genes, indicating
that there is an uncoupling of cell proliferation and expression of
cell cycle genes (Narita et al, 2003). Thus, p16/Rb links SAHF
formation and cell cycle gene silencing. Consistent with this,
heterochromatin markers are accumulated on the promoters of the
cell cycle genes during senescence (Narita et al, 2003; Rastogi et al,
2006). It is particularly worth noting that similar heterochroma-
tinisation of some E2F-target genes was observed in a differentia-
tion model (Ait-Si-Ali et al, 2004). These findings lead to a model
in which active epigenetic rearrangement results in an alteration of
the gene expression profile that contributes to the establishment
and maintenance of new phenotypes during senescence and
differentiation.
CHROMATIN ASSEMBLY AND SAHFS
Adams and co-workers further characterised SAHFs and showed
that macroH2A is enriched in SAHFs (Zhang et al, 2005) (Figure 3).
The macroH2A is a transcriptionally repressive variant of histone
H2A and, in female mammals, a marker of the inactive X (Xi)
chromosome, which is a form of facultative heterochromatin
(Costanzi and Pehrson, 1998). In fact, in ras-induced senescent
cells, Xi is indistinguishable from other DAPI-staining foci,
although a substantial difference in the components of SAHFs
and Xi has been noted, where Xi is enriched for Polycome Group
proteins and histone H3 K27me3 (which provides a docking site
for Polycomb proteins), rather than HP1/histone H3 K9me3 (Plath
et al, 2003). Further understanding of the commonalities and
differences between SAHFs and Xi might confer insights into the
structural and functional diversity of heterochromatin. It also
remains to be elucidated how macroH2A contributes to the
senescence phenotype and how, if at all, macroH2A is involved in
the tumour suppressor machinery.
In addition to macroH2A, the authors also showed that histone
chaperons, Asf1a and HIRA, play a critical role in SAHF formation,
although the precise molecular mechanism is unknown (Zhang
et al, 2005) (Figure 3). Interestingly, during senescence, HIRA and
HP1 dynamically localise to promyelocytic leukaemia nuclear
bodies (PML bodies), another senescence effector. Currently, the
exact function of PML bodies and how PML bodies are involved in
the senescence programme is not clear, but it has been suggested
that PML bodies are sites for macromolecular assembly and
Nucleosome
macroH2A
Histone H3 K9me3
HP1
HMGA architecture
HP1
HIRA Rb?
Rb?
PML body
SAHF
Figure 3 Model of SAHF formation. Senescence-associated hetero-
chromatic foci contains a variety of chromatin proteins, such as K9-
methylated histone H3 and HP1 (heterochromatic markers), macroH2A
(histone variant) and HMGA proteins (architectural proteins). HP1 and
HIRA (histone chaperon) transiently localise to PML bodies. Interestingly,
Rb, which binds HP1, is also known to localise to PML bodies, although
how PML bodies are involved in senescence is unknown.
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been speculated that the transient localisation of HP1 might be a
prerequisite for the subsequent accumulation of HP1 in SAHFs
(Zhang et al, 2005). The histone chaperones might also be
involved, either directly or indirectly, in the nucleosome re-
assembly during senescence, such as macroH2A deposition.
CHROMATIN ARCHITECTURE AND SENESCENCE
More recently, another twist came from the biochemical analysis of
chromatin-associated proteins in senescent cells (Narita et al,
2006). The experiments revealed that high-mobility group A
(HMGA) proteins are senescence-associated chromatin binding
proteins and that HMGA proteins are essential structural
components of SAHFs (Figure 3). Furthermore, HMGA-dependent
SAHF formation contributes to the stable senescence arrest.
Interestingly, SAHF-positive cells also lose linker histone H1,
which is known to compete with HMGA in binding DNA
(Funayama et al, 2006).
The HMGA1 and HMGA2 proteins are non-histone architectural
chromatin proteins, and have three ‘AT-hook’ domains that are
responsible for binding to the minor groove of AT-rich DNA
sequences (Reeves, 2001). HMGA proteins are not transcription
factors per se, but have so-called ‘architectural transcription factor’
activity, which is associated with their ability to facilitate assembly
of the ‘enhanceosome’ and typically create an ‘open’ chromatin
environment conducive to transcription.
Moreover, HMGA has been linked to cellular proliferation and is
known as an oncogene (Mantovani et al, 1998; Reeves, 2001). For
example, expression of HMGA is induced by growth factor or
serum stimulation (Lanahan et al, 1992). Both HMGA genes are
highly expressed in proliferating cells in the embryo or in many
tumours, and are downregulated upon cellular differentiation
(Zhou et al, 1995; Reeves, 2001). Furthermore, HMGA proteins can
promote tumorigenicity both in vitro (Takaha et al, 2004) and
in vivo (Fedele et al, 2005, 2006b), and gene amplifications and
translocations of HMGA genes occur in many human cancers
(Reeves, 2001).
Therefore, the specific accumulation of HMGA proteins on
chromatin during senescence and the functional association of
HMGA with the senescence phenotype were initially puzzling
(Narita et al, 2006). Although, HMGA can be induced by mitogenic
stimuli, the upregulation of HMGA during ras-senescence is not a
natural consequence of the constitutively active ras-MAPK
cascade, as HMGA upregulation and the accumulation of the gene
products on chromatin can be induced by other senescence-
inducing stimuli, such as DNA damage and replicative stress. In
addition, the kinetics of HMGA2 accumulation on chromatin
during ras-senescence is progressive and coincides with the timing
of SAHF formation.
Strikingly, knockdown of HMGA1 abolishes SAHF architecture
completely, whereas HMGA2 knockdown has a lesser impact.
Interestingly, chemicals that bind the minor groove of AT
sequences of DNA displace HMGA proteins from chromatin and
dissolve SAHFs in senescent cells. Surprisingly, HP1 accumulation
on the chromatin fraction persists after dissolution of SAHFs by
removal of HMGA, suggesting that the condensation of higher
order chromatin and the global accumulation of biochemical
markers of heterochromatin might be separable events during
SAHF formation. Consistent with this observation, overexpression
of HP1 alone fails to induce SAHF formation. These data raise an
interesting question; how relevant is the higher-order architecture
of SAHF for the senescence phenotype? Although SAHF formation
requires p16, depletion of p16 in senescent cells (after establish-
ment of SAHFs) has little impact on SAHFs as well as E2F-target
gene expression, indicating that p16 is only required for establish-
ment, but not for maintenance of SAHFs (Narita et al, 2006).
However, p16 knockdown can de-silence some E2F-targets if
SAHFs are dissolved by depletion of HMGA1, suggesting that
HMGA1 may contribute to the silencing of these genes, at least in
part, by regulating higher-order chromatin structure to modify the
accessibility of transcriptional regulators. In accordance with these
data, codepletion of p16 and HMGA1 causes a higher incidence of
senescence bypass, demonstrating a cooperative effect of HMGA1
and p16 on stable senescence arrest.
These data indicate that HMGA proteins may be both pro- and
antioncogenic, depending on the cellular context. Consistent with
this view, both Hmga1 transgenic mice and Hmga1 knockout mice
develop haematologic malignant tumours (Fedele et al, 2005,
2006a). Interestingly, HMGA2 is located near the HDM2 and CDK4
loci on chromosome 12q13–15 and is often coamplified with both
HDM2 and CDK4 (Berner et al, 1997), which target the p53 and
p16/Rb pathways, respectively. Indeed, overexpression of HDM2
and CDK4 can cancel the HMGA2-induced senescence at least
in vitro, although HMGA2 does not add further proliferative
advantage to the HDM2- and CDK4-expressing cells. Furthermore,
when the senescence programme is completely abrogated by E1A
oncoprotein, ectopic HMGA2 promotes transformation activity of
ras both in vitro and in vivo (Narita et al, 2006).
How exactly HMGA can be oncogenic and tumour suppressive
depending on the cellular context is unknown. Interestingly a
recent paper indicates that in tumour cells HMGA2 physically
associates with Rb and activates E2F-target genes by inhibiting the
function of Rb, a negative regulator of E2F-target genes (Fedele
et al, 2006b). This is in marked contrast to the senescence setting
where HMGA2 upregulation is associated with repression of
E2F-target genes (Narita et al, 2006). Although it is yet to be tested
if HMGA2 and Rb physically interact during senescence, under-
standing how HMGA2 has opposing activities on E2F-target
expression depending on the context might give new insights
into the role of chromatin architecture in senescence and
tumorigenesis.
Deregulation of HMGA proteins in tumour tissues is not limited
to malignant tissue, but in fact many benign tumours, particularly
of mesenchymal origin, are accompanied by HMGA upregulation.
Given the dual function of HMGA and the discovery of OIS in a
benign context, it is very attractive to speculate that HMGA
upregulation is an early event in response to oncogenic stimuli
during tumorigenesis and contributes to the activation of the
senescence programme. If this process is successful, tumours
would remain benign and would not progress to a malignant stage.
However, additional mutations that disable the senescence
programme, such as disruption of the p53 and p16/Rb pathways,
would promote tumour progression and reveal the oncogenic
activity of HMGA.
Chromatin alterations and in vivo senescence
Although in vivo validation of these individual components of
SAHF is yet to be tackled, SAHF-like chromatin alterations were
identified in some cases of in vivo OIS (Collado et al, 2005;
Lazzerini Denchi et al, 2005). In addition, Schmitt and co-workers
revealed a functional involvement of epigenetic regulation in OIS
and tumour suppression in vivo (Braig et al, 2005). Using the
Em-N-ras transgenic mouse model, they showed that disruption of
Suv39h1 histone methyltransferase, which is responsible for the
histone H3 K9me3 heterochromatic mark, dramatically accelerates
ras-induced T-cell lymphomagenesis. This data is consistent with
the idea that the ras signalling could provoke the Suv39h1-
dependent senescence machinery, which blocks ras-mediated
tumorigenicity. Indeed, they also showed in vitro that ras
expressing lymphoid cells exhibit a senescence phenotype with
SAHF-like chromatin alteration, which is inhibited by Suv39h1
knockout.
Cellular senescence and chromatin organisation
M Narita
689
British Journal of Cancer (2007) 96(5), 686–691 & 2007 Cancer Research UKFurthermore, combined treatment of the same transgenic mice
with inhibitors of DNA methyltransferases and histone deacety-
lases, enzymes that are associated with gene silencing and
heterochromatin, showed a similar effect to that seen by disruption
of Suv39h1 in ras-mediated T-cell lymphomagenesis. Although the
precise mechanism by which epigenetic alterations are involved
in antilymphomagenesis is unknown, and it is not clear to what
extent we can generalise these observations, these data further our
knowledge on the effector mechanism of senescence in vivo.
CONCLUDING REMARKS
To date, treatment for cancer has focused on the removal and/or
killing of cancer cells. Inducing senescence could be an additional
therapeutic approach. Given the fact, however, that both the p53
and p16/Rb pathways, which are critical for senescence machinery,
are often abrogated in tumours, targeting downstream events,
such as chromatin alterations, would be more promising.
Independent studies have identified different factors that are
involved in SAHF formation (Figure 3). However, there is no
insight into functional and structural association among those
factors. Understanding how these individual factors contribute to
senescence and tumour suppression as a network will be a
challenge in the years to come.
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